- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
51 result(s) found for: Immunological memory.
Displaying page 1 of 3.
EudraCT Number: 2014-004013-85 | Sponsor Protocol Number: ZKSJ0073 | Start Date*: 2016-03-21 | |||||||||||
Sponsor Name:Friedrich Schiller University Jena | |||||||||||||
Full Title: Sequential versus simultaneous vaccination with pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPV23) in unvaccinated older adults: Immunological memory and antibod... | |||||||||||||
Medical condition: previously unvaccinated older healthy adults | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005355-32 | Sponsor Protocol Number: IIV-275 | Start Date*: 2014-03-06 |
Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands) | ||
Full Title: Memory response against Bordetella pertussis in adults: immunological effects of an acellular pertussis booster vaccination | ||
Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-008104-41 | Sponsor Protocol Number: 112801 | Start Date*: 2009-07-03 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III long-term follow-up study to assess immunological memory induced following primary and booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT), ... | ||
Medical condition: Subjects aged 31-44 months previously vaccinated with GSK Biologicals’ 10Pn-PD-DiT vaccine and age-matched unprimed children who participated in study 10PN-PD-DIT-014 (107137). | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004122-70 | Sponsor Protocol Number: 04M107 | Start Date*: 2005-11-15 |
Sponsor Name:Great Ormond Street Hospital | ||
Full Title: Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. | ||
Medical condition: Ataxia Telangiectasia (AT) is a genetic condition in which there is a deficiency of the immune system with excessive susceptibility to pneumonia and other infections. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004970-24 | Sponsor Protocol Number: 2012-004970-24 | Start Date*: 2013-04-19 | |||||||||||
Sponsor Name:Fundació Clinic per a la Recerca Biomèdica | |||||||||||||
Full Title: Virological and immunological safety of a dose reduction strategy antiretroviral regimen with efavirenz / tenofovir / emtricitabine | |||||||||||||
Medical condition: HIV -1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004073-27 | Sponsor Protocol Number: 18082A0002 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:ARCI (trade name LYON RECHERCHE CLINIQUE : LyREC) | |||||||||||||
Full Title: Dupilumab impact on skin resident memory T cells | |||||||||||||
Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004370-85 | Sponsor Protocol Number: 104083 | Start Date*: 2005-01-25 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, multicentric open study to evaluate the immunological memory induced by a 3-dose primary vaccination followed by a booster dose with GSK Biologicals’ 11-valent conjugate pneumococcal v... | ||
Medical condition: A single dose of Aventis Pasteur’s 23-valent pneumococcal polysaccharide vaccine (Pneumo 23) to healthy children who were either primed with the 3-dose primary vaccination followed by the booster d... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000560-93 | Sponsor Protocol Number: 106623 | Start Date*: 2006-06-27 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIa, open, multicentre study to evaluate the immunological memory induced in healthy children following a 3-dose primary vaccination with either GSK Biologicals’ 10-valent pneumococcal con... | ||
Medical condition: A single dose of Sanofi Pasteur MSD’s unconjugated 23-valent polysaccharide pneumococcal vaccine (Pneumovax™23) to healthy children who were previously primed with the full three doses of GSK Biolo... | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002103-15 | Sponsor Protocol Number: VAC-259 | Start Date*: 2011-09-07 |
Sponsor Name:RIVM | ||
Full Title: Development of humoral and cellular immune response in infants after pneumococcal conjugate vaccinations with Synflorix® or Prevenar-13® | ||
Medical condition: Immunity and immune memory after pneumococcal vaccination against S. pneumoniae serotypes present in either Synflorix or Prevenar-13 | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004445-17 | Sponsor Protocol Number: hCMV2013 | Start Date*: 2014-03-05 | |||||||||||
Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE | |||||||||||||
Full Title: A PROSPECTIVE RANDOMIZED STUDY FOR PREDICTING HUMAN CYTOMEGALOVIRUS (hCMV) INFECTION ACCORDING TO BASELINE hCMV-SPECIFIC T-CELL RESPONSE IN KIDNEY TRANSPLANT PATIENTS | |||||||||||||
Medical condition: cytomegalovirus infection in renal tranplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003052-36 | Sponsor Protocol Number: 105555 | Start Date*: 2005-11-18 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of... | ||
Medical condition: Booster vaccination against Streptococcus pneumoniae in healthy children having previously received vaccines as a primary 3-dose vaccination course in the study 11PN-PD-DIT-002. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001104-36 | Sponsor Protocol Number: IIV-291 | Start Date*: 2016-06-01 |
Sponsor Name:RIVM | ||
Full Title: Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands | ||
Medical condition: immunological response to an extra mumps immunization (in healthy volunteers) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003588-69 | Sponsor Protocol Number: W2018.034 | Start Date*: 2019-03-07 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: The ENDURRANCE-1 Study. Exploring durable remission with rituximab in ANCA associated vasculitis | ||
Medical condition: ANCA associated vasculitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001327-23 | Sponsor Protocol Number: ITP0815 | Start Date*: 2015-06-26 | |||||||||||
Sponsor Name:Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto | |||||||||||||
Full Title: Eltrombopag as Second line Therapy in adult patients with primary Immune Thrombocytopenia (ESTIT study) in an attempt to achieve long-term remission: a single arm multicenter phase II clinical and ... | |||||||||||||
Medical condition: Primary Immune Thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005392-34 | Sponsor Protocol Number: 111345, 111346, 111347 | Start Date*: 2008-02-11 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A phase III long-term follow-up study to assess antibody persistence and immunological memory in children previously vaccinated with four doses of pneumococcal conjugate vaccine in primary vaccinat... | ||||||||||||||||||
Medical condition: Subjects who participated in booster study 10PN-PD-DiT-007 in Poland and who received the full vaccination course (i.e. four doses) with a pneumococcal vaccine, co-administered with DTPa-HBV-IPV/Hi... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-001638-34 | Sponsor Protocol Number: navaboost | Start Date*: 2006-09-28 |
Sponsor Name:Health Protection Agency | ||
Full Title: A phase IV, single group study to evaluate the magnitude of antibody response, its persistence and avidity maturation following meningococcal serogroup C conjugate booster vaccination in older chil... | ||
Medical condition: Meningococcal Group C Disease | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-003678-42 | Sponsor Protocol Number: IIV-316 | Start Date*: 2017-09-01 |
Sponsor Name:RIVM [...] | ||
Full Title: Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands... | ||
Medical condition: Pertussis infection | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) FI (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004785-98 | Sponsor Protocol Number: OVG2008/5 | Start Date*: 2008-12-22 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: An observational study of children immunised in infancy against hepatitis B virus, evaluating the persistence of immunity and the immune response to a scheduled booster dose of hepatitis B vaccine | |||||||||||||
Medical condition: The intended application of Engerix B is active immunisation against Hepatitis B virus infection caused by all known subtypes in non immune subjects. | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002476-40 | Sponsor Protocol Number: 17-APN-01 | Start Date*: 2019-05-07 | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: Personalized Medicine for Membranous Nephropathy PMMN | |||||||||||||
Medical condition: Idiopathic Membranous Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004187-30 | Sponsor Protocol Number: CO17730 | Start Date*: 2011-12-14 | |||||||||||
Sponsor Name:Avraham Pharmaceuticals Ltd. | |||||||||||||
Full Title: A 36-month, multi-centre, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of low dose Ladostigil in patients with Mild Cognitive Impairment (MCI) | |||||||||||||
Medical condition: Patient with Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
